Zdrowie i gospodarka · 14/12/2022

FDA Renews Endocrinologic and Metabolic Drugs Advisory Committee for 2 Years

The FDA is renewing the Endocrinologic and Metabolic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on August 27, 2024, following a determination by the Commissioner of Food and Drugs that it is in the public interest.